In the last trading session, 0.16 million shares of the Carisma Therapeutics Inc (NASDAQ:CARM) were traded, and its beta was 1.60. Most recently the company’s share price was $0.44, and it changed around -$0.02 or -3.46% from the last close, which brings the market valuation of the company to $18.40M. CARM currently trades at a discount to its 52-week high of $2.77, offering almost -529.55% off that amount. The share price’s 52-week low was $0.38, which indicates that the current value has risen by an impressive 13.64% since then. We note from Carisma Therapeutics Inc’s average daily trading volume that its 10-day average is 0.24 million shares, with the 3-month average coming to 263.32K.
Carisma Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.60. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 4 recommended CARM as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Carisma Therapeutics Inc is expected to report earnings per share of -0.16 for the current quarter.
Carisma Therapeutics Inc (NASDAQ:CARM) trade information
Instantly CARM has showed a red trend with a performance of -3.46% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.4808 on recent trading dayincreased the stock’s daily price by 8.49%. The company’s shares are currently up 5.23% year-to-date, but still down -6.47% over the last five days. On the other hand, Carisma Therapeutics Inc (NASDAQ:CARM) is 2.46% up in the 30-day period. We can see from the shorts that 0.54 million shares have been sold at a short interest cover period of 1.32 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 92.67% from its current value. Analyst projections state that CARM is forecast to be at a low of $6 and a high of $6.
Carisma Therapeutics Inc (CARM) estimates and forecasts
Carisma Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -61.34 percent over the past six months and at a 49.03% annual growth rate that is well above the industry average of 16.60%. The year-over-year growth rate is expected to be 43.48%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 5.42M in revenue for the current quarter. 2 analysts expect Carisma Therapeutics Inc to make 4.69M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 4.29M and 3.4M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 26.40%. Forecasts for the next quarter put sales growth at 38.14%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 24.98%.
CARM Dividends
Carisma Therapeutics Inc’s next quarterly earnings report is expected to be released in February.
Carisma Therapeutics Inc (NASDAQ:CARM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 27.40% of Carisma Therapeutics Inc shares, and 31.47% of them are in the hands of institutional investors. The stock currently has a share float of 43.34%.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 1.05 shares worth $0.46 million, making up 2.53% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 342.63 shares worth around $0.15 million, which represents about 0.82% of the total shares outstanding.
